

30 December 2024

## Privatisation by way of merger

## Disclosure of dealings in the shares of Shanghai Henlius Biotech, Inc.

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

Party	Date	Description of	Description of	Nature of dealings	Number of	Maturity date /	Reference	Total amount	Resultant
		relevant	products		reference	closing out	price	paid / received	balance
		securities			securities to	date			(including those
					which the				of any person
					derivatives				with whom there
					relate				is an agreement
									or
									understanding)
CICC	27 December	Derivatives	Other types of	Closing out of a	164,000	22 January	\$23.8385	\$3,909,513.5500	241,500
Financial	2024		products	derivative contract		2025			
Trading		Derivatives	Other types of	Closing out of a	164,000	2 January 2026	\$23.8474	\$3,910,974.0000	241,500
Limited			products	derivative contract					

End



## Note:

CICC Financial Trading Limited is an exempt principal trader connected with the Offeror.

Dealings were made for its own account.

CICC Financial Trading Limited is ultimately owned by China International Capital Corporation Limited.